CDK4 and neoplasm: It is, therefore, still interesting to investigate whether senescent cancer cells induced by CDK4/6i treatment have a stronger ability to create the anti‐tumor immune microenvironment compared to other conventional chemotherapeutic DNA‐damaging agents.